

# PARP-1 polyclonal antibody

This antibody is covered by our [Worry-Free Guarantee](#).

Citations: 45

[View Online »](#)

## Ordering Information


[Order Online »](#)

ALX-210-302-R100

100µl


## Manuals, SDS & CofA

[View Online »](#)



**Figure:** Western blot using rabbit polyclonal anti PARP-1.


- Lane 1: recombinant human PARP-1 (ALX-201-053, 5 ng).
- Lane 2: Total HeLa cell extract.
- Lane 3: Total MEF PARP1+/+ cell extract.
- Lane 4: Total MEF PARP1-/- cell extract.
- Lane 5: Lysate (50 µg) from HeLa cells.
- Lane 6: Lysate (50 µg) from HeLa PARP-1sh cells.
- Lane 7: Lysate (50 µg) from HeLa cells treated for 8 hours with Doxorubicin 5 µg/ml.
- Lane 8: Lysate (50 µg) from HEK293 cells.
- Lane 9: Lysate (50 µg) from HEK293 cells.
- Lane 10: Lysate (50 µg) from HEK293 cells transfected with PARP-1 siRNA.
- Lane 11: Lysate (50 µg) from HEK293 cells transfected with control siRNA.



The PARP-1 BRCT domain is required for immunoglobulin gene conversion.(A) Schematic of the domains of PARP-1 and variants dAMD and dBRCT. (B) Western blot showing levels of PARP-1 and AID expression with  $\beta$  actin as a loading control. (C) Survival of PARP-1 variants to MMS-induced DNA damage. Experiment was performed in triplicate and error bars represent SEM. \*\*\*  $p < .0001$  compared to WT or dBRCT; †  $p < .0001$  compared to WT or dBRCT,  $p = .02$  compared to dAMD. There is no significant difference between WT and dBRCT. (D) Frequencies of gene conversion events as a proportion of total mutations at the IgL locus (+/- SEM).  $n$  = total number of mutations analyzed for each cell line.


Image collected and cropped by CiteAb under a CC-BY license from the following publication: The BRCT domain of PARP-1 is required for immunoglobulin gene conversion. *PLoS Biol* (2010)

C



Functional effects of expression of human PARP-1 variants on survival in response to MMS-induced DNA damage. (A) Schematic of domains of human PARP-1 and variants. The functional domains of PARP-1 consist of a DNA binding domain (DBD), automodification domain (AMD), BRCT protein interaction domain (BRCT), and WGR/catalytic domain (WGR/Cat). The DBD contains 3 zinc finger domains, which are unusual in that they have specificity for DNA structure rather than sequence and recognize single strand breaks (SSBs) or double strand breaks (DSBs) [39],[40]. The AMD contains the lysine residues that act as poly-ADP-ribose (PAR) acceptors [35]. The WGR/catalytic domain catalyzes PAR formation when the DBD is bound to DNA, and PARylation of the AMD is thought to serve as a signal to recruit DNA repair enzymes such as XRCC1 as well as facilitates the release of PARP-1 from the site of DNA damage [41]. The BRCT protein interaction domain is of unknown function, as it has been shown to be dispensable for PARP-1's DNA repair functions in previous analyses [16]. hPARP: full length human PARP-1; dZF2: C125Y and C128Y mutations to prevent folding of the second zinc finger domain; DBDCat: DNA binding domain fused to a non-functional portion of the catalytic domain. (B) MMS survival assay comparing survival of the PARP-1 variants to MMS-induced DNA damage. Survival is measured by the ability to proliferate after 1 h of exposure to MMS at the indicated concentration. The experiment was performed in triplicate; error bars represent SEM. \*\*\* PARP-1-/-, dZF2, and hPARP p<.0001 compared to WT; PARP-1-/- p<.0003 compared to hPARP; † p<.0001 compared to WT, p = .021 compared to PARP-1-/-; between PARP-1-/- and dZF2 there is no significant difference. (C) Western blot showing levels of variant PARP-1 and AID expression with β actin as a loading control.

B



AID overexpression does not restore GCV to PARP-1-/- cells. (A) Gene conversion frequencies (+/- SEM) in cell lines overexpressing ggAID. n = total number of mutations analyzed for each cell line. The total number of sequences analyzed was 169 WT, 137 PARP-1-/-, and 106 hPARP. (B) Western blot showing increase in AID expression upon transduction with ggAID retrovirus. (C) IgL transcript levels (mean +/- SEM) are similar in cell lines which do and do not support GCV. \* p<.05, ns = not significant compared to hPARP. (D) AID expression levels do not directly influence GCV frequencies. Blue bars are AID expression levels (mean +/- SEM) before (dark blue) and after (light blue) transduction with ggAID cDNA as measured by Western blot and quantified by LICOR Odyssey infrared imaging, normalized to β actin. Brown bars are GCV frequencies (mean +/- SEM) before (dark brown) and after (light brown) transduction with ggAID cDNA as a percentage of total mutations observed for the indicated cell lines. \*\*\* p<.0001, \* p<.05, ns = not significant.

Image collected and cropped by CiteAb under a CC-BY license from the following publication: The BRCT domain of PARP-1 is required for immunoglobulin gene conversion. *PLoS Biol* (2010)



## Handling & Storage

**Use/Stability** Stable for at least one year when stored at +4°C.

**Handling** Avoid freeze/thaw cycles.

**Long Term Storage** +4°C

**Shipping** Blue Ice

## Regulatory Status

RUO - Research Use Only

## Product Details

**Alternative Name** Poly(ADP-ribose) polymerase-1

**Application** ELISA, ICC, IHC (FS), IHC (PS), IP, WB

**Application Notes** Detects bands of ~116kDa (PARP-1) and ~85kDa (apoptosis-induced cleavage fragment) by Western blot.

**Crossreactivity** Does not cross-react with PARP-2.

**Formulation** Liquid. Neat serum containing 0.02% sodium azide.

**Host** Rabbit

**Immunogen** Recombinant human PARP-1 (poly(ADP-ribose) polymerase-1) (aa 1-1014).

**Recommendation Dilutions/Conditions** Immunocytochemistry (1:4,000)Immunoprecipitation (1:400)Western Blot (1:4,000)Suggested dilutions/conditions may not be available for all applications.Optimal conditions must be determined individually for each application.

**Species Reactivity** Bovine, Human, Monkey, Mouse

**UniProt ID** P09874

**Worry-free Guarantee** This antibody is covered by our [Worry-Free Guarantee](#)



ENZO LIFE SCIENCES,  
INC.  
Phone: 800.942.0430  
[info-  
usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

European Sales Office  
ENZO LIFE SCIENCES  
(ELS) AG  
Phone: +41 61 926 8989  
[info-  
eu@enzolifesciences.com](mailto:info-eu@enzolifesciences.com)

Belgium, The Netherlands  
& Luxembourg  
Phone: +32 3 466 0420  
[info-  
be@enzolifesciences.com](mailto:info-be@enzolifesciences.com)

France  
Phone: +33 472 440 655  
[info-  
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

Germany  
Phone: +49 7621 5500 526  
[info-  
de@enzolifesciences.com](mailto:info-de@enzolifesciences.com)

UK & Ireland  
Phone (UK customers):  
0845 601 1488  
Phone: +44 1392 825900  
[info-  
uk@enzolifesciences.com](mailto:info-uk@enzolifesciences.com)